Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company focused on developing next-generation cell therapies and immunotherapies targeting cancer, having entered the public markets via a SPAC de-merger transaction. The company filed its Form 10-K annual report with the SEC on March 14, 2023, reflecting its status as a post-combination operating entity in the healthcare and biotechnology sector. Estrella's pipeline centers on novel immunological approaches to oncology, positioning it within a competitive field of clinical-stage biotech companies that have chosen the SPAC route to access public capital markets. For full filing history, deal timelines, sponsor details, and comparable de-SPAC transaction data on ESLA and thousands of other companies, sign up for complete access at SpacDesk.